A study released on Monday reveals that semaglutide, the active component of the diabetic and weight-loss medications Ozempic and Wegovy, may be associated with better smoking cessation. Weight Loss Drug News in USA
The likelihood of semaglutide users accessing healthcare for tobacco use problems was lower than that of users of glucagon-like peptide-1 (GLP-1) receptor agonists and Type 2 diabetes medications such as insulin and metformin. Additionally, they had a lower likelihood of using medication and counseling to stop smoking. Weight Loss Drug News in USA
Within the first 30 days of receiving a prescription for semaglutide, there were the greatest disparities in smoking cessation behaviors between users of this medication and those on other antidiabetic medications.
The authors concluded that more clinical trials are necessary to assess semaglutide’s potential for treating tobacco use disorder (TUD).
The semaglutide may have increased people’s aversion to nicotine, the addictive substance found in tobacco, while decreasing their enjoyment of smoking, according to the scientists’ conjecture.
Professor Rong Xu of Case Western Reserve University in Cleveland, the study’s principal author, told The Epoch Times that patient stories about how the drug made them feel less of a want to smoke initially inspired her to undertake this research. Weight Loss Drug News in USA
The authors discovered a link between the prescription of semaglutide and the refusal to receive medical attention, therapy, or medicine to help people quit smoking.
Semaglutide is a GLP-1 medication that functions by imitating the body’s natural GLP-1 hormone. In addition to lowering blood sugar and increasing satiety and insulin release, GLP-1 has also been demonstrated to decrease hunger.
When compared to other non-GLP-1 antidiabetic medications such as insulin, metformin, sodium-glucose cotransporters, sulfonylureas, and the like, the connection with quitting smoking was especially strong.
